Navigation Links
Omni Bio Pharmaceutical Intends to Expand Type 1 Diabetes Trial to 50 Patients
Date:2/28/2011

DENVER, Feb. 28, 2011 /PRNewswire/ -- (OTC Bulletin Board: OMBP) Omni Bio Pharmaceutical, Inc. ("Omni Bio"), an emerging biopharmaceutical company formed to acquire, license, and develop existing therapies for indications with substantial commercialization potential, has committed to expand its Phase I/II human clinical trial in recently diagnosed Type 1 diabetes patients from 15 patients to 50.

The expansion of the trial population has been approved by the FDA.  The trial, which is currently underway at the Barbara Davis Center for Childhood Diabetes ("BDC") at the University of Colorado-Denver Anschutz Medical Campus, has seen improvement in the condition of the first enrolled patients.  Based on observations of the first enrolled patients at BDC, Omni Bio intends to expand the patient enrollment to 50 patients, which may involve obtaining a second trial site.

Dr. James Crapo Omni Bio's Chief Executive Officer stated, "We are currently engaged in discussions related to expanding our Type 1 diabetes trial from the initially targeted 15 patients to a total of 50 patients.  The expansion of the trial will cause a substantially greater amount of statistically relevant scientific data to be generated, allowing us to better assess our next steps in pursuing this indication."

The expansion of the clinical trial would result in an increase of clinical trial service costs of approximately $2 million, excluding drug costs, and would require Omni Bio to raise additional financing before the expansion of the trial can begin.  There is no assurance that Omni Bio will be able to raise additional capital to fund the expansion of the clinical trial on acceptable terms or at all.

Omni Bio is also pleased to announce that it has received letters of intent for human clinical trials at a number of institutions in the United States and Europe, contingent
'/>"/>

SOURCE Omni Bio Pharmaceutical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... --  Cypher Genomics, Inc., the genome informatics company, ... as chief technology officer. Ravenel has more than ... a proven track record of designing and architecting solutions ... been recognized as a top designer and architect of ... for delivering innovative products that operate at scale and ...
(Date:10/1/2014)... Oct. 1, 2014 Ardelyx, Inc. ... biopharmaceutical company focused on cardio-renal, gastrointestinal and ... its 371 patient Phase 2b clinical trial ... bowel syndrome (IBS-C).  Results from this study ... in IBS-C symptoms for tenapanor-treated patients compared ...
(Date:9/30/2014)... This report analyzes the worldwide markets for Enteral ... Enteral Feeding Pumps, Nasogastric Tubes, and Others. The ... Japan , Europe , ... and Rest of World. Annual estimates and forecasts are provided ... analysis is provided for these markets. The report ...
Breaking Medicine Technology:Cypher Genomics Appoints J. Patrick Ravenel Chief Technology Officer 2Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 2Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 3Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 4Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 5Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 6Global Enteral Feeding Devices Industry 2Global Enteral Feeding Devices Industry 3Global Enteral Feeding Devices Industry 4Global Enteral Feeding Devices Industry 5Global Enteral Feeding Devices Industry 6Global Enteral Feeding Devices Industry 7Global Enteral Feeding Devices Industry 8Global Enteral Feeding Devices Industry 9Global Enteral Feeding Devices Industry 10Global Enteral Feeding Devices Industry 11Global Enteral Feeding Devices Industry 12Global Enteral Feeding Devices Industry 13Global Enteral Feeding Devices Industry 14Global Enteral Feeding Devices Industry 15Global Enteral Feeding Devices Industry 16Global Enteral Feeding Devices Industry 17Global Enteral Feeding Devices Industry 18Global Enteral Feeding Devices Industry 19
(Date:10/2/2014)... -- Genes may interact with stress to trigger heart disease ... risk occurs in about 13 percent of people, but only ... people reduce their heart disease risk through simple measures such ... Duke University researchers said. The study authors analyzed genetic ... between variations in the EBF1 gene and higher levels of ...
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, Oct. 1, ... the stops to rescue surgical patients in crisis are ... such heroism is questionable, a new study suggests. ... saving elderly patients with life-threatening complications after major surgery, ... senior author Dr. Amir Ghaferi. He is assistant professor ...
(Date:10/1/2014)... more than 80 per cent of bowel cancers could ... that medicines called ,JAK inhibitors, halted tumour growth in ... in more than 80 per cent of bowel cancers. ... clinical trials, for diseases including rheumatoid arthritis, psoriasis, blood ... second-most common cancer in Australia with nearly 17,000 people ...
(Date:10/1/2014)... (October 1, 2014) Despite a policy focus ... developmental disabilities, this vulnerable population continues to have ... The Journal of the American Dental Association ... and Tufts University School of Dental Medicine report ... influencing at-home oral care provided by caregivers to ...
(Date:10/1/2014)... October 01, 2014 Bedros Keuilian is ... Boot Camp fitness boot camps, he’s also considered the ... , with sold out business summits, a line of ... consultant to a recent Spike TV reality show to ... now is the time for personal trainers and fitness ...
Breaking Medicine News(10 mins):Health News:Genes May Make Some More Prone to Heart Disease When Under Stress 2Health News:'High-Intensity' Hospitals Save More Elderly After Surgery: Study 2Health News:'High-Intensity' Hospitals Save More Elderly After Surgery: Study 3Health News:Eighty percent of bowel cancers halted with existing medicines 2Health News:To improve oral health of adults with developmental disabilities, support caregivers 2Health News:To improve oral health of adults with developmental disabilities, support caregivers 3Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 2Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 3
... science of diagnosing pain causing a number of pain ... University of Cincinnati is examining the diagnosis of pain ... that can result for the patient. The ... Department of Sociology, was presented today at the 105th ...
... 16, 2010) -- Researchers at Rice University have won federal ... whether a disease outbreak is caused by a natural pathogen ... The three-year grant -- Rice,s first from the Defense ... and public health officials with the tools they need to ...
... National Science Foundation (NSF) has awarded $3 million to ... research program on stem cell bio-manufacturing. The program is ... production, in order to meet the anticipated demand for ... Graduate Education and Research Traineeship (IGERT) Program, which supports ...
... We all want that summer glow that comes from a day ... implications for our health. Now Dr. Niva Shapira of Tel Aviv ... in the sun safer ― and it,s all in our food. ... Dr. Shapira has shown that a diet rich in antioxidants and ...
... to own their failure. It,s time for us to change ... advance warning to the old, big spending, do nothing, me ... 2008 College Station, TXAugust 16, 2010Change and hope were ... new longitudinal study published in the September issue of ...
... what causes the birth of a human fat cell is ... have come up with a few predictions about the proteins ... increase understanding of how and why preadipocytes, or pre-fat cells, ... the findings eventually could lead to a way to freeze ...
Cached Medicine News:Health News:How badly does it hurt? Research examines the biomedical diagnosis of pain 2Health News:Telltale signs of bioterror 2Health News:NSF awards stem cell bio-manufacturing research and education program to Georgia Tech 2Health News:NSF awards stem cell bio-manufacturing research and education program to Georgia Tech 3Health News:SPF on your plate 2Health News:SPF on your plate 3Health News:Presidential election outcomes directly influence suicide rates 2Health News:Scientists closer to finding what causes the birth of a fat cell 2Health News:Scientists closer to finding what causes the birth of a fat cell 3
... GE Healthcare's new Vivid 7 Dimension cardiovascular ... to give clinicians the first fully integrated ... Vivid 7 Dimension, a latest member of ... new tools for detecting and diagnosing heart ...
... The innovative B-Twin Expandable Spinal System ... fusion procedures. The Implant - preloaded on ... the prepared intervertebral space in a reduced ... then EXPANDED up to 15mm (depending on ...
... Rhe Vivid 7 system is GEs premier ... level of image quality to echocardiography, and ... confidence to clinicians.,By listening to customer input, ... the first ergonomically-designed cardiovascular system that delivers ...
... invented the guidewire-mounted pressure sensor and ... Sensor is the only sensor on ... and flow. With significantly improved maneuverability ... your primary guidewire, as well as ...
Medicine Products: